Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance

References

• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 2017;8:561.
   PubMed Web of Science ®Google Scholar
• McLachlan J. Immune checkpoint inhibitors and their side effects. Pathology 2019;51:S17.
   Google Scholar
• FDA, U.S. Timeline of Anti-PD-1/L1 Antibody Approvals by the FDA. MAY 20, 2O21. Available from: https://www.cancerresearch.org/en-us/scientists/immuno-oncology-landscape/fda-approval-timeline-of-active-immunotherapies.
   Google Scholar
• Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018;360:k793.
   PubMedGoogle Scholar
• Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018;19:345–361.
   PubMed Web of Science ®Google Scholar
• Plachouri K-M, Vryzaki E, Georgiou S. Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview. Curr Drug Saf 2019;14:14–20.
   PubMed Web of Science ®Google Scholar
• Sibaud V, Boulinguez S, Riffaud L, et al. Dermatologic toxicities of immune checkpoint inhibitors. In: Annales de Dermatologie et de Venereologie. California: PotozkinMD Skincare Center; 2018.
   Google Scholar
• Sibaud V, Meyer N, Lamant L, et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016;28:254–263.
   PubMed Web of Science ®Google Scholar
• Chadha S, Para AJ, Choi J. Management of immune-related cutaneous adverse reactions to PD-1 and PD-L1 inhibitors for the inpatient dermatologist. Curr Derm Rep 2020;2020:1–13.
   Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714.
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563–580.
   PubMed Web of Science ®Google Scholar
• Carlos G, Anforth R, Chou S, et al. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res 2015;25:265–268.
   PubMed Web of Science ®Google Scholar
• Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 2017;41:125–128.
   PubMed Web of Science ®Google Scholar
• Miraglia E, Soda G, Giustini S. Genital lichen sclerosus after nivolumab. Dermatol Online J 2020;26:516.
   Google Scholar
• Lee M, Seetharamu N. An atypical presentation of lichen planus-like reaction from pembrolizumab. Case Rep Dermatol Med 2019;2019:437.
   Google Scholar
• Yılmaz M, Ş, Güven Meşe U. Çelik Nivolumab-induced lichen planus. 2020.
   Google Scholar
• Veronesi G, Scarfì F, Misciali C, et al. An unusual skin reaction in uveal melanoma during treatment with nivolumab: extragenital lichen sclerosus. Anticancer Drugs 2019;30:969–972.
   PubMedGoogle Scholar
• Nguyen ED, Xue YK, Danesh M, et al. A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies. Dermatopathology (Basel) 2019;6:255–259.
   PubMedGoogle Scholar
• van Damme C, Sibaud V, André J, et al. Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: histopathologic description. JAAD Case Rep 2021;10:110.
   PubMedGoogle Scholar
• Ferguson L, Ho B, Weir J, et al. Extensive mucocutaneous, oesophageal and otic lichen planus secondary to nivolumab therapy. Skin Health and Disease 2021;1:e8.
   Google Scholar
• Liu R, Consuegra G, Chou S, et al. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Clin Exp Dermatol 2019;44:643–646.
   PubMedGoogle Scholar
• Komori T, Honda T, Irie H, et al. Multiple erosive lichen planus preceded by solitary lichen planus after combination therapy with nivolumab and radiation. J Eur Acad Dermatol Venereol 2017;31:e382–e384.
   PubMedGoogle Scholar
• Tetzlaff MT, Nagarajan P, Chon S, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am J Dermatopathol 2017;39:121–129.
   PubMedGoogle Scholar
• Kwon CW, Murthy RK, Kudchadkar R, et al. Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma. JAAD Case Rep 2020;6:1045–1047.
   PubMedGoogle Scholar
• Coscarart A, Martel J, Lee MP, et al. Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus. J Cutan Pathol 2020;47:275–279.
   PubMedGoogle Scholar
• Chapman S, Ashack K, Dapprich DC. Hypertrophic Lichen planus-like eruption following pembrolizumab. Cutis 2021;107:E10–E11.
   PubMedGoogle Scholar
• Sethi A, Raj M. Pembrolizumab-induced lichenoid dermatitis in a patient with metastatic cancer of unknown primary. Cureus 2021;13:768.
   Google Scholar
• Fixsen E, Patel J, Selim MA, et al. Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine. Oncologist 2019;24:e103.
   PubMedGoogle Scholar
• Sugawara A, Koga H, Abe T, et al. Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment. J Dermatol 2021;48:401–404.
   PubMedGoogle Scholar
• Esfahani K, Berg MH, Zargham H, et al. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report. J Immunother Cancer 2021;9:831.
   Google Scholar
• Marques-Piubelli ML, Tetzlaff MT, Nagarajan P, et al. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: a diagnostic pitfall for superficially invasive squamous cell carcinoma. J Cutan Pathol 2020;47:954–959.
   PubMedGoogle Scholar
• Schmidgen MI, Butsch F, Schadmand‐Fischer S, et al. Pembrolizumab-induzierter Lichen planus pemphigoides bei einem Patienten mit metastasiertem Melanom. J Dtsch Dermatol Ges 2017;15:742–745.
   Google Scholar
• Cardis MA, Jiang H, Strauss J, et al. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report. BMC Cancer 2019;19:1–5.
   PubMedGoogle Scholar
• Manko S, Côté B, Provost N. A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: a case report. SAGE Open Med Case Rep 2021;9:2050313X21993279.
   PubMedGoogle Scholar
• Myrdal CN, Sundararajan S, Curiel-Lewandrowski C. Widespread hypertrophic lichen planus following programmed cell death ligand 1 blockade. Case Rep Dermatol 2020;12:119–123.
   PubMedGoogle Scholar
• Shakhbazova A, Hinds B, Marsch AF. Lichenoid inflammation of DSAP lesions following treatment with durvalumab, olaparib, and paclitaxel: a potential diagnostic pitfall mimicking lichenoid drug eruptions associated with PDL-1 inhibitors. Dermatology Online Journal 2020;26:982.
   Google Scholar
• Danlos F-X, Pagès C, Baroudjian B, et al. Nivolumab-induced sarcoid-like granulomatous reaction in a patient With Advanced Melanoma. Chest 2016;149:e133–e136.
   PubMedGoogle Scholar
• Montaudié H, Pradelli J, Passeron T, et al. Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol 2017;176:1060–1063.
   PubMed Web of Science ®Google Scholar
• Gkiozos I, Kopitopoulou A, Kalkanis A, et al. Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol 2018;13:1076–1082.
   PubMed Web of Science ®Google Scholar
• Diaz-Perez JA, Beveridge MG, Victor TA, et al. Granulomatous and lichenoid dermatitis after IgG4 anti‐PD‐1 monoclonal antibody therapy for advanced cancer. J Cutaneous Pathol 2018;45:434–438.
   PubMedGoogle Scholar
• Honigman AD, Lai F, Elakis J, Prall O, et al. Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient. 2019.
   Google Scholar
• Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, et al. Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res 2018;28:230.
   PubMed Web of Science ®Google Scholar
• Takamori S, Furubayashi N, Taguchi K, et al. Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab. Thorac Cancer 2021;12(14):2122–2125.
   PubMedGoogle Scholar
• Yousuf H, Mekki R, Khan K, et al. Pembrolizumab-induced sarcoid-like reaction in a patient with lung cancer. Cureus 2020;2020:12–12.
   Google Scholar
• Muacevic A, Adler J, Yousuf H, et al. Pembrolizumab-induced sarcoid-like reaction in a patient with lung cancer. Cureus 2021;12:1.
   Web of Science ®Google Scholar
• van Baar ML, Guminski AD, Ferguson PM, et al. Pembrolizumab for cutaneous squamous cell carcinoma: report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation. JAAD Case Rep 2019;5:491.
   PubMedGoogle Scholar
• Lomax AJ, McGuire HM, McNeil C, et al. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis. Int J Rheum Dis 2017;20:1277–1285.
   PubMed Web of Science ®Google Scholar
• Laroche A, Alarcon Chinchilla E, Bourgeault E, et al. Erythema nodosum as the initial presentation of nivolumab-induced sarcoidosis-like reaction. J Cutan Med Surg 2018;22:627–629.
   PubMedGoogle Scholar
• Noguchi S, Kawachi H, Yoshida H, et al. Sarcoid-like granulomatosis induced by nivolumab treatment in a lung cancer patient. Case Rep Oncol 2018;11:562–566.
   PubMedGoogle Scholar
• Paolini L, Poli C, Blanchard S, et al. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment. j Immunotherapy Cancer 2018;6:1–5.
   PubMedGoogle Scholar
• Mitchell MA, Hogan K, Amjadi K. Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma. Immunotherapy 2018;10:1189–1192.
   PubMedGoogle Scholar
• Min ST, Nordman II, Tran HA. Hypercalcaemia due to sarcoidosis during treatment with avelumab for metastatic Merkel cell carcinoma. Case Rep Oncol 2019;12:639–643.
   PubMedGoogle Scholar
• Balestra R, Benzaquen S, Wang J. Sarcoidosis-like granulomatous lung reaction associated with anti-programmed death receptor-1 ligand therapy. Ann Am Thorac Soc 2017;14:296–299.
   PubMedGoogle Scholar
• Sanderson E, Wimaleswaran H, Senko C, et al. Durvalumab induced sarcoid-like pulmonary lymphadenopathy. Respirol Case Rep 2020;8:e00542.
   PubMedGoogle Scholar
• Sobash P, Desikan R, Kakkera K. Single-dose durvalumab induced sarcoidosis-like reaction with granuloma in non-small cell lung cancer. Chest 2020;158:A1518.
   Google Scholar
• Rousseau PM, Raimbourg J, Robert M, et al. First case of cutaneous sarcoidosis within tattoos under durvalumab. Int J Dermatol 2019;58:e168–e170.
   PubMedGoogle Scholar
• Budnick, I. Sturek J., Hilar and mediastinal lymphadenopathy due to sarcoid-like reaction in Patient Receiving Durvalumab. In: TP36. TP036 What drug caused that? Case reports in drug-induced lung disease. American Thoracic Society; 2021 p. A2131-A2131.
   Google Scholar
• Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016;152:45–51.
   PubMed Web of Science ®Google Scholar
• Boniface K, et al. Vitiligo-like lesions in patients receiving anti-programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo. J Am Acad Dermatol 2018;78:e17–e18.
   PubMedGoogle Scholar
• Nishino K,Ohe S, Kitamura M, et al. Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung. J Thorac Dis 2018;10:E481.
   PubMedGoogle Scholar
• Lolli C, Medri M, Ricci M, et al. Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma. Medicine 2018;97:810.
   Google Scholar
• Billon E, Walz J, Brunelle S, et al. Vitiligo adverse event observed in a patient with durable complete response after nivolumab for metastatic renal cell carcinoma. Front Oncol 2019;9:1033.
   PubMedGoogle Scholar
• Yin ES, Totonchy MB, Leventhal JS. Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding. JAAD Case Rep 2017;3:90–92.
   PubMedGoogle Scholar
• Uenami T, Hosono Y, Ishijima M, et al. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report. Lung Cancer 2017;109:42–44.
   PubMedGoogle Scholar
• Zafar Z, Vogler C, Hudali T, et al. Nivolumab-associated acute demyelinating encephalitis: a case report and literature review. Clin Med Res 2019;17:29–33.
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P, Huang H, Tsiouda T, et al. Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma. Respir Med Case Rep 2017;22:283–286.
   PubMedGoogle Scholar
• Miyagawa T, Kadono T, Masui Y, et al. Nivolumab-induced vitiligo successfully treated with narrowband UVB phototherapy. Eur J Dermatol 2017;27:656–658.
   PubMedGoogle Scholar
• Kosche C, Mohindra N, Choi JN. Vitiligo in a patient undergoing nivolumab treatment for non-small cell lung cancer. JAAD Case Rep 2018;4:1042–1044.
   PubMedGoogle Scholar
• Bulat V, Likic R, Bradic L, et al. Pembrolizumab-induced vitiligo in a patient with lung adenocarcinoma: a case report. Br J Clin Pharmacol 2020;87(6):2614–2618.
   PubMedGoogle Scholar
• Wolner Z, Marghoob AA, Pulitzer MP, et al. A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol 2018;178:265–269.
   PubMedGoogle Scholar
• Yun SJ, Oh IJ, Park CK, et al. Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report. Transl Lung Cancer Res 2020;9:1585.
   PubMedGoogle Scholar
• Nakamura Y, Teramoto Y, Asami Y, et al. Nivolumab therapy for treatment-related vitiligo in a patient with relapsed metastatic melanoma. JAMA Dermatol 2017;153:942–944.
   PubMed Web of Science ®Google Scholar
• Rkman D, Likić R, Bebek M, et al. Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma: a case report. Croat Med J 2019;60:552.
   PubMedGoogle Scholar
• Ebia MI, Choi JN. Dermatologic reactions to novel immune checkpoint inhibitors. Curr Derm Rep 2018;7:227–238.
   Google Scholar
• Belum V, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016;60:12–25.
   PubMed Web of Science ®Google Scholar
• Donaldson M, Owen JL, Chae YK, et al. Management of persistent pruritus and lichenoid reaction secondary to nivolumab with narrowband ultraviolet B phototherapy. Front Oncol 2018;8:405.
   PubMedGoogle Scholar
• Bieber AK, Yin L, Sicco KL. Pruritus and tense bullae after discontinuation of pembrolizumab in a patient with renal cell carcinoma. Jama 2020;324:1453–1454.
   PubMedGoogle Scholar
• Kwatra SG, Ständer S, Kang H. PD-1 blockade-induced pruritus treated with a mu-opioid receptor antagonist. N Engl J Med 2018;379:1578–1579.
   PubMed Web of Science ®Google Scholar
• Ito J, et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer 2017;109:58–61.
   PubMed Web of Science ®Google Scholar
• Ohtsuka M, Miura T, Mori T, et al. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol 2015;151:797–799.
   PubMed Web of Science ®Google Scholar
• De Bock M, Hulstaert E, Kruse V, et al. Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor: case report and literature review. Case Rep Dermatol 2018;10:190–197.
   PubMed Web of Science ®Google Scholar
• Sapalidis K, Kosmidis C, Michalopoulos N, et al. Psoriatic arthritis due to nivolumab administration a case report and review of the literature. Respir Med Case Rep 2018;23:182–187.
   PubMedGoogle Scholar
• Nigro O, Pinotti G, Gueli R, et al. Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature. Immunotherapy 2020;12:549–554.
   PubMedGoogle Scholar
• Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129:1339–1350.
   PubMed Web of Science ®Google Scholar
• Monsour EP, Pothen J, Balaraman R. A novel approach to the treatment of pembrolizumab-induced psoriasis exacerbation: a case report. Cureus 2019;11:824.
   Google Scholar
• Siciliano MA, Dastoli S, d’Apolito M, et al. Pembrolizumab-induced psoriasis in metastatic melanoma: activity and safety of apremilast, a case report. Front Oncol 2020;10:445.
   PubMedGoogle Scholar
• Suzuki M, Matsumoto S, Takeda Y, et al. Systemic psoriasiform dermatitis appeared after the administration of pembrolizumab. Intern Med 2020;59:871–872.
   PubMedGoogle Scholar
• Johnson D, Patel AB, Uemura MI, et al. IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol Res 2019;7:860–865.
   PubMedGoogle Scholar
• Ma VT, Katzman CS, Palmbos PL, et al. NB-UVB phototherapy in the treatment of anti-PD-1 inhibitor-induced psoriasis: a case report. Current Problems in Cancer: Case Reports 2020;1:100004.
   Google Scholar
• Bonigen J, Raynaud-Donzel C, Hureaux J, et al. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 2017;31:e254–e257.
   PubMed Web of Science ®Google Scholar
• Voudouri D, Nikolaou V, Laschos K, et al. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer 2017;41:407–412.
   PubMed Web of Science ®Google Scholar
• Yamamoto T. Anti-programmed cell death-1-induced plaque and guttate psoriasis. Indian J Dermatol 2018;63:88.
   PubMedGoogle Scholar
• Di Altobrando A, Bruni F, Alessandrini A, et al. Severe de-novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma. Dermatol Ther 2020;33:e13363.
   PubMedGoogle Scholar
• Politi A, Angelos D, Mauri D, et al. A case report of psoriasis flare following immunotherapy: report of an important entity and literature review. SAGE Open Med Case Rep 2020;8:2050313X19897707.
   PubMedGoogle Scholar
• Ichiki N, Tanabe T, Hisada S, et al. A case of readministration of nivolumab by treating with apremilast for psoriasiform eruption as irAE. J Cutan Immunol Allergy 2021;4:67–68.
   Google Scholar
• George A, George R. Nivolumab (PD-1 Inhibitor) induced exacerbation of psoriasis. Indian Dermatol Online J 2020;11:261–262.
   PubMedGoogle Scholar
• C Guven D, Kilickap S, Guner G, et al. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer. J Oncol Pharm Pract 2020;26:256–258.
   PubMedGoogle Scholar
• Glinos GD, Fisher WS, Morr CS, et al. Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma. JAAD Case Reports 2021;11:74.
   PubMedGoogle Scholar
• Om A, Cardon B, Cohen G. Psoriasiform eruption on the face and extremities associated with nivolumab therapy. JAAD Case Rep 2018;4:373.
   PubMedGoogle Scholar
• Fattore D, Annunziata MC, Panariello L, et al. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast. Eur J Cancer 2019;110:107–109.
   PubMedGoogle Scholar
• Iijima S, Miyazaki K, Sato S, et al. A case of de novo psoriasis induced by atezolizumab in a patient with advanced lung cancer. J Cutan Immunol Allergy 2019;2:178–179.
   Google Scholar
• Miyamoto D, Santi CG, Aoki V, et al. Bullous pemphigoid. An Bras Dermatol 2019;94:133–146.
   PubMed Web of Science ®Google Scholar
• Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 2018;79:1081–1088.
   PubMed Web of Science ®Google Scholar
• Rofe O, Bar‐Sela G, Keidar Z, et al. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Clin Exp Dermatol 2017;42:309–312.
   PubMedGoogle Scholar
• Thomsen K, Diernaes J, Øllegaard TH, et al. Bullous pemphigoid as an adverse reaction to pembrolizumab: two case reports. Case Rep Dermatol 2018;10:154–157.
   PubMed Web of Science ®Google Scholar
• Bezinelli LM, Eduardo FP, Migliorati CA, et al. A severe, refractory case of mucous membrane pemphigoid after treatment with pembrolizumab: brief communication. J Immunother 2019;42:359–362.
   PubMedGoogle Scholar
• Sun CW, Grossman SK, Aphale A, et al. Pembrolizumab-induced bullous pemphigoid. JAAD Case Rep 2019;5:362.
   PubMedGoogle Scholar
• Qiu C, Shevchenko A, Hsu S. Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis. JAAD Case Rep 2020;6:400.
   PubMedGoogle Scholar
• Hara K, Yamasaki K, Yamada S, et al. Bullous pemphigoid in a patient treated with pembrolizumab. Intern Med 2020;59:139–140.
   PubMedGoogle Scholar
• Muto Y, Namikawa K, Fujiwara Y, et al. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: a case report. J Dermatol 2020;47:e9–e11.
   PubMedGoogle Scholar
• Cardona AF, Ruiz-Patiño A, Zatarain-Barron ZL, et al. Refractory bullous pemphigoid in a patient with metastatic lung adenocarcinoma treated with Pembrolizumab. Case Rep Oncol 2021;14:386–390.
   PubMedGoogle Scholar
• Morris LM, Lewis HA, Cornelius LA, et al. Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: a case series. J Cutan Pathol 2020;47:742–746.
   PubMedGoogle Scholar
• Singer S, Nelson CA, Lian CG, et al. Nonbullous pemphigoid secondary to PD-1 inhibition. JAAD Case Rep 2019;5:898.
   PubMedGoogle Scholar
• Bandino J, Perry DM, Clarke CE, et al. Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology. J Eur Acad Dermatol Venereol 2017;31:e378–e380.
   PubMedGoogle Scholar
• Wada N, Uchi H, Furue M. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII. J Dermatol 2017;44:e240–e241.
   PubMedGoogle Scholar
• Haug V, Behle V, Benoit S, et al. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma. Br J Dermatol 2018;179:993–994.
   PubMed Web of Science ®Google Scholar
• Zumelzu C, Alexandre M, Le Roux C, et al. Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1/ programmed death-ligand 1:A case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature. Front Med 2018;5:268.
   PubMed Web of Science ®Google Scholar
• Panariello L, Fattore D, Annunziata MC, et al. Bullous pemphigoid and nivolumab: dermatologic management to support and continue oncologic therapy. Eur J Cancer 2018;103:284–286.
   PubMed Web of Science ®Google Scholar
• Wu X, Palvai S, Jalil A. Nivolumab-induced severe bullous pemphigoid in a patient with renal cancer: a case report and literature review. Jcmt 2020;6:77.
   Google Scholar
• Palla AR, Smith E, Doll D. Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma. Immunotherapy 2019;11:1187–1192.
   PubMedGoogle Scholar
• Sadik CD, Langan EA, Grätz V, et al. Checkpoint inhibition may trigger the rare variant of anti-LAD-1 IgG-positive, anti-BP180 NC16A IgG-negative bullous pemphigoid. Front Immunol 2019;10:1934.
   PubMedGoogle Scholar
• Ito M, Hoashi T, Endo Y, et al. Atypical pemphigus developed in a patient with urothelial carcinoma treated with nivolumab. J Dermatol 2018;46:e90–e92.
   PubMedGoogle Scholar
• Krammer S, Krammer C, Salzer S, et al. Recurrence of pemphigus vulgaris under nivolumab therapy. Front Med (Lausanne) 2019;6:262.
   PubMedGoogle Scholar
• Lopez AT, Geskin L. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1/programmed death ligand-1 inhibitors and recommendations for diagnosis and management. Oncologist 2018;23:1119.
   PubMed Web of Science ®Google Scholar
• Sowerby L, Dewan AK, Granter S, et al. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol 2017;153:603–605.
   PubMed Web of Science ®Google Scholar
• Kosche C, Owen JL, Sadowsky LM, et al. Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature. Dermatol Online J 2019;25:817.
   Google Scholar
• Leavitt E, Holland V. A case of atezolizumab-induced photodistributed bullous pemphigoid. Dermatol Ther 2019;32:e12924.
   PubMedGoogle Scholar
• Russo I, Sacco G, Frega S, et al. Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab. Eur J Dermatol 2017;27:205–208.
   PubMedGoogle Scholar
• Kudo F, Watanabe Y, Iwai Y, et al. Advanced lung adenocarcinoma with nivolumab-associated dermatomyositis. Intern Med 2018;57:2217–2221.
   PubMed Web of Science ®Google Scholar
• Kosche C, Stout M, Sosman J, et al. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature. Melanoma Res 2020;30:313–316.
   PubMedGoogle Scholar
• DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 2020;82:267–281.
   PubMedGoogle Scholar
• Kao L, Chung L, Fiorentino DF. Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep 2011;13:225–232.
   PubMed Web of Science ®Google Scholar
• Zarkavelis G, Mauri D, Karassa F, et al. The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature. Contemp Oncol (Pozn) 2020;24:75.
   PubMedGoogle Scholar
• Krathen M, Fiorentino D, Werth V. Dermatomyositis. Dermatol Immun 2008;10:313–332.
   Google Scholar
• Luo Y-B, Mastaglia FL. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta 2015;1852:622–632.
   PubMed Web of Science ®Google Scholar
• Messer A, Drozd B, Glitza IC, et al. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature. Dermatol Online J 2020;26:887.
   Google Scholar
• Shibata C, Kato J, Toda N, et al. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report. J Med Case Reports 2019;13:1–6.
   PubMedGoogle Scholar
• Osaki M, Tachikawa R, Ohira J, et al. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: a case report. Invest New Drugs 2021;39:251–255.
   PubMedGoogle Scholar
• Asano R, Shinoda K, Tsuda R, et al. Anti-TIF1γ antibody-positive dermatomyositis in a 15-year-old boy with Epstein–Barr virus-related nasopharyngeal cancer receiving nivolumab. Rheumatology 2020;60(6):e197–e199.
   Google Scholar
• Kadota H, Gono T, Shirai Y, et al. Immune checkpoint inhibitor-induced myositis: a case report and literature review. Curr Rheumatol Rep 2019;21:10–9.
   PubMed Web of Science ®Google Scholar
• Marano A, Clarke JM, Morse MA, et al. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. Br J Dermatol 2019;181:580–583.
   PubMed Web of Science ®Google Scholar
• Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother 2018;41:208–211.
   PubMed Web of Science ®Google Scholar
• Takatsuki K, Yanagihara T, Egashira A, et al. A rare case of pembrolizumab-induced dermatomyositis in a patient with cancer of unknown primary origin. Am J Case Rep 2021;22:e930286.
   PubMedGoogle Scholar
• Wiggins CJ, Chon SY. Dermatomyositis, pembrolizumab, and squamous cell carcinoma of the lung. Baylor University Medical Center Proceedings. Taylor & Francis; 2021.
   Google Scholar
• Berger M, Legeay AL, Souci S, et al. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma. Eur J Cancer 2018;104:227–230.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Aso M, Nagasawa H, et al. Atezolizumab-associated dermatomyositis in advanced lung small-cell carcinoma. Intern Med 2021;2021:6917–6920.
   Google Scholar
• Imai R, Ikemura S, Jinta T. Anti-TIF1γ antibody-positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers. Respirol Case Rep 2021;9:e00736.
   PubMedGoogle Scholar
• Kristjansdottir H, Steinsson K, Gunnarsson I, et al. Lower expression levels of the programmed death 1 receptor on CD4 + CD25+ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:1702–1711.
   PubMed Web of Science ®Google Scholar
• Blakeway EA, Elshimy N, Muinonen-Martin A, et al. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. Melanoma Res 2019;29:338–341.
   PubMedGoogle Scholar
• Shao K, McGettigan S, Elenitsas R, et al. Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD-1 therapy. J Cutan Pathol 2018;45:74–77.
   PubMed Web of Science ®Google Scholar
• Jono M, Kinehara Y, Utsu Y, et al. Neuropsychiatric immune-related adverse events induced by pembrolizumab in a patient with lung adenocarcinoma and systemic lupus erythematosus. Intern Med 2020;59:569–572.
   PubMedGoogle Scholar
• Kurokawa M, Naito S, Ito S, et al. Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus. IJU Case Rep 2020;3:181–183.
   PubMedGoogle Scholar
• Zitouni NB, Arnault JP, Dadban A, et al. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res 2019;29:212–215.
   PubMed Web of Science ®Google Scholar
• Tagliamento M, Grossi F, Paolino S, et al. Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. Immunotherapy 2019;11:873–879.
   PubMedGoogle Scholar
• Wouters A, Durieux V, Kolivras A, et al. Bullous lupus under Nivolumab treatment for lung cancer: a case report with systematic literature review. Anticancer Res 2019;39:3003–3008.
   PubMedGoogle Scholar
• Riano I, Cristancho C, Treadwell T. Stevens-Johnson syndrome–like reaction after exposure to pembrolizumab and recombinant zoster vaccine in a patient with metastatic lung cancer. J Invest Med High Impact Case Rep 2020;8:2324709620914796.
   Google Scholar
• Saw S, Lee HY, Ng QS. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer 2017;81:237–239.
   PubMed Web of Science ®Google Scholar
• Hwang A, Iskandar A, Dasanu CA. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. J Oncol Pharm Pract 2019;25:1520–1522.
   PubMedGoogle Scholar
• Ryu S, Jun I, Kim TI, et al. Pembrolizumab-induced Stevens-Johnson Syndrome with severe ocular complications. Ocular Immunology and Inflammation 2021;2021:1–3.
   Google Scholar
• Kimura H, Hasegawa A, Takei I, et al. Characteristic pathological features of keratinocyte death in a case of Stevens-Johnson syndrome manifested by an immune checkpoint inhibitor. J Eur Acad Dermatol Venereol 2021;35:e142–e145.
   PubMedGoogle Scholar
• Robinson S, Saleh J, Curry J, et al. Pembrolizumab-induced stevens-johnson syndrome/toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: a case report. Am J Dermatopathol 2020;42:292–296.
   PubMedGoogle Scholar
• Cai ZR, Lecours J, Adam JP, et al. Toxic epidermal necrolysis associated with pembrolizumab. J Oncol Pharm Pract 2020;26:1259–1265.
   PubMedGoogle Scholar
• OConnor C, Jordan E, O’Connell M. Atypical Stevens-Johnson syndrome caused by pembrolizumab in the treatment of metastatic melanoma–Are corticosteroids a safe treatment option? J Dermatol Dermatol Surg 2020;24:137.
   Google Scholar
• Storandt MH, Seth R. A case of Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving chemo-immunotherapy with pemetrexed and pembrolizumab. Current Problems in Cancer: Case Reports 2021;3:100048.
   Google Scholar
• Hsu T-J, Liu K-L. Stevens-Johnson syndrome and toxic epidermal necrolysis related to immune checkpoint inhibitors: two cases and literature review. Dermatol Sin 2020;38:236.
   Google Scholar
• Kumar R, Bhandari S. Pembrolizumab induced toxic epidermal necrolysis. Curr Probl Cancer 2019;2019:100478–100478.
   Google Scholar
• Dasanu CA. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. J Oncol Pharm Pract 2019;25:2052–2055.
   PubMed Web of Science ®Google Scholar
• Shibata A, Yoshikawa T, Makita S, et al. A case of recurrent Stevens-Johnson syndrome caused by nivolumab therapy. Eur J Dermatol 2019;2019:1.
   Google Scholar
• Gracia-Cazaña T, Padgett E, Calderero V, et al. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer. Dermatol Online J 2021;27:77.
   Google Scholar
• Takeda Y, et al. Two Cases of Stevens-Johnson Syndrome after Nivolumab Therapy for Gastric Cancer. Gan to Kagaku Ryoho 2021;48:154–156.
   PubMedGoogle Scholar
• Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 2017;44:381–384.
   PubMed Web of Science ®Google Scholar
• Chirasuthat P, Chayavichitsilp P. Atezolizumab-induced Stevens-Johnson syndrome in a patient with non-small cell lung carcinoma. Case Rep Dermatol 2018;10:198–202.
   PubMedGoogle Scholar
• Maloney NJ, Ravi V, Cheng K, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol 2020;59:e183–e188.
   PubMed Web of Science ®Google Scholar
• Owosho AA, Randazzo J, Rosen EB, et al. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab. Oral Oncol 2016;63:e1.
   PubMedGoogle Scholar
• Bhattacharyya I, Chehal H, Migliorati C. Severe oral erosive lichenoid reaction to pembrolizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2020;130:e301–e307.
   PubMedGoogle Scholar
• Shazib MA, Woo SB, Sroussi H, et al. Oral immune-related adverse events associated with PD-1 inhibitor therapy: a case series. Oral Dis 2020;26:325–333.
   PubMedGoogle Scholar
• Sibaud V, Eid C, Belum VR, et al. Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings. J Eur Acad Dermatol Venereol 2017;31:e464.
   PubMedGoogle Scholar
• Economopoulou P, Nicolatou-Galitis O, Kotsantis I, et al. Nivolumab-related lichen planus of the lip in a patient with head and neck cancer. Oral Oncol 2020;104:104623.
   PubMedGoogle Scholar
• Enomoto Y, Nakatani H, Kondo S, et al. Drug-induced oral lichenoid reaction during nivolumab therapy. Int J Oral Maxillofac Surg 2019;48:488–491.
   PubMed Web of Science ®Google Scholar
• Yamanaka S,Nakao K, Ninomiya A, et al. A case of an oral lichenoid reaction during nivolumab therapy. J Oral Maxillofac Surg Med Pathol 2020;32:521–524.
   Google Scholar
• Spinelli A, Gissi DB, Rossi R, et al. A case of nivolumab-associated oral lichenoid lesions. Multidisciplinary Digital Publishing Institute Proceedings 2019;35:76.
   Google Scholar
• Abedalthagafi M. Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies. Oncotarget 2018;9:35458.
   PubMedGoogle Scholar
• Kebudi R, Amayiri N, Abedalthagafi M, et al. Position paper: challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low-resource settings. Pediatr Blood Cancer 2020;67:e28309.
   PubMedGoogle Scholar
• Paul C, Chakraborty S, Chakraborty S, et al. Constitutional mismatch repair deficiency syndrome in a patient from India. Clin Case Rep 2020;8:2824–2826.
   PubMedGoogle Scholar
• Aydın F, Görükmez O, Kiraz AH, et al. Glioblastoma and colorectal adenocarcinoma in an adolescent girl with constitutional mismatch repair deficiency syndrome mimicking neurofibromatosis Type-I. J Pediatr Acad 2020;1:34–38.
   Google Scholar
• Petrelli F, Signorelli D, Ghidini M, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers 2020;12:546.
   Google Scholar
• Pan EY, Merl MY, Lin K. The impact of corticosteroid use during anti-PD1 treatment. J Oncol Pharm Pract 2020;26:814–822.
   PubMed Web of Science ®Google Scholar